bioatla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. the culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our conditionally active biologics (cab) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. this improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. bioatla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.
Company profile
Ticker
BCAB
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
851922320
BCAB stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
26 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Bioatla Reports Fourth Quarter and Full Year 2023 Financial Results
26 Mar 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
8-K
Other Events
12 Feb 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
8 Jan 24
8-K
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
13 Dec 23
8-K
Other Events
4 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
Transcripts
BCAB
Earnings call transcript
2023 Q4
26 Mar 24
BCAB
Earnings call transcript
2023 Q3
7 Nov 23
BCAB
Earnings call transcript
2023 Q2
1 Aug 23
BCAB
Earnings call transcript
2023 Q1
11 May 23
BCAB
Earnings call transcript
2022 Q4
23 Mar 23
BCAB
Earnings call transcript
2022 Q3
3 Nov 22
BCAB
Earnings call transcript
2022 Q2
13 Aug 22
BCAB
Earnings call transcript
2022 Q1
7 May 22
Latest ownership filings
SC 13D/A
Soleus Private Equity Fund I, L.P.
16 Apr 24
4
Scott Andrew Smith
1 Apr 24
4
Eric Sievers
1 Apr 24
4
Scott Andrew Smith
1 Mar 24
4
Eric Sievers
1 Mar 24
4
RICHARD A WALDRON
20 Feb 24
4
Christian Vasquez
20 Feb 24
4
Eric Sievers
20 Feb 24
4
JAY M PHD SHORT
20 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 141.28 mm | 141.28 mm | 141.28 mm | 141.28 mm | 141.28 mm | 141.28 mm |
Cash burn (monthly) | 9.14 mm | 3.07 mm | 11.67 mm | 10.81 mm | 9.12 mm | 8.20 mm |
Cash used (since last report) | 60.84 mm | 20.44 mm | 77.73 mm | 71.98 mm | 60.70 mm | 54.63 mm |
Cash remaining | 80.44 mm | 120.84 mm | 63.55 mm | 69.30 mm | 80.59 mm | 86.66 mm |
Runway (months of cash) | 8.8 | 39.4 | 5.4 | 6.4 | 8.8 | 10.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 89 |
Opened positions | 7 |
Closed positions | 12 |
Increased positions | 28 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 50.85 bn |
Total shares | 50.42 mm |
Total puts | 10.10 k |
Total calls | 66.20 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Himalaya Parent | 8.68 mm | $456.69 mm |
Soleus Capital Management | 4.36 mm | $7.41 bn |
Tang Capital Management | 3.78 mm | $6.42 bn |
Tang Capital Partners | 3.12 mm | $0.00 |
BLK Blackrock | 3.11 mm | $5.29 bn |
Soleus Private Equity Fund I | 3.05 mm | $10.81 mm |
Vanguard | 2.10 mm | $3.57 bn |
Adage Capital Partners GP, L.L.C. | 1.80 mm | $3.05 bn |
Zone II Healthcare | 1.73 mm | $60.54 mm |
MS Morgan Stanley | 1.60 mm | $2.72 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Smith Scott Andrew | Common Stock | Payment of exercise | Dispose F | No | No | 3.44 | 2,181 | 7.50 k | 292,455 |
31 Mar 24 | Eric Sievers | Common Stock | Payment of exercise | Dispose F | No | No | 3.44 | 572 | 1.97 k | 210,422 |
29 Feb 24 | Smith Scott Andrew | Common Stock | Payment of exercise | Dispose F | No | No | 2.7 | 2,181 | 5.89 k | 294,636 |
29 Feb 24 | Eric Sievers | Common Stock | Payment of exercise | Dispose F | No | No | 2.7 | 572 | 1.54 k | 210,994 |
31 Jan 24 | Smith Scott Andrew | Common Stock | Payment of exercise | Dispose F | No | No | 1.92 | 2,181 | 4.19 k | 296,817 |